Skip to Content

Sefelsa Approval Status

  • FDA approved: No
  • Brand name: Sefelsa
  • Generic name: gabapentin
  • Dosage form: Extended Release Tablets
  • Previous name: Serada
  • Company: Depomed, Inc.
  • Treatment for: Postmenopausal Symptoms

Sefelsa (gabapentin) is an investigational extended-release formulation of gabapentin in development for the treatment of menopausal hot flashes.

Development Status and FDA Approval Process for Sefelsa

Jun  3, 2013FDA Issues Complete Response Letter on Sefelsa New Drug Application
Mar  4, 2013Depomed Provides Update on Sefelsa FDA Advisory Committee
Oct 15, 2012Depomed Announces Serada NDA Acceptance and FDA Advisory Committee Meeting
Aug 17, 2012Depomed Announces Submission Of Serada NDA
Apr 18, 2012Depomed Announces Intent to File NDA for Serada for Treatment of Menopausal Hot Flashes

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.